Many existing and emerging cancer therapies have a significant effect on the cardiovascular health of patients with cancer and cancer survivors. This paper examines current aspects of interdisciplinary cardio-oncology clinical care delivery and education in the United States and outlines how these data provide a platform for future development of the field. We 
The aim of this paper is to summarize the key current aspects of interdisciplinary cardio-oncology clinical care delivery and education in the United States and to outline how these data provide a platform for future development of the field. As part of the ACC's strategic mission to provide a professional home for CV specialists, we examine existing interests and expertise, as well as available forums and opportunities for education and knowledge exchange. This paper does not present a comprehensive review of the considerable clinical or research publications within cardio-oncology, but rather a snapshot of the needs and opportunities in patient care, training, and education in this field. We then discuss potential next steps to advance the field and interdisciplinary collaboration.
THE ORIGINS OF CARDIO-ONCOLOGY OR ONCO-CARDIOLOGY
The terms "cardio-oncology" and "onco-cardiology" have both been used to describe this field, encompassing a continuum of CV risk stratification, prevention, and treatment that spans the timeline from cancer diagnosis into survivorship ( Figure 1 ) and that depends on close collaboration across cardiology and oncology specialties (1) (2) (3) . The origins of the field date back to the late 1960s, when anthracyclines, potent new antitumor compounds, were widely introduced into the therapeutic regimens of many cancers (4) (5) (6) .
Observations of their dose-dependent cardiotoxic effects not only led to critical modifications of anthracycline-based regimens with cumulative dose limits (7), but also spurred research directed toward the understanding, diagnosis, and prevention of cardiac toxicity. Anthracycline-induced cardiac injury became a prototype of what later was named type I cancer therapy-related cardiac dysfunction, characterized by ultrastructural evidence of necrosis, dose dependence, and largely irreversible effects on cardiac muscle (8, 9) . In contrast, type II cancer therapy-related cardiac dysfunction is associated with the use of molecularly targeted cancer therapeutics, the effects of which are not dose related, do not have molecular evidence of necrosis, and are often reversible (8, 9) .
Since these early clinical and pathological observations, our knowledge about cardiotoxicity has seen impressive growth fueled by molecular investigations of traditional and numerous new cancer therapeutics (10) (11) (12) , translational research using biomarkers and imaging for CV prediction and risk stratification (13) (14) (15) (16) (17) (18) , clinical trials evaluating the effects of cardioprotective strategies (19) (20) (21) (22) , as well as epidemiologic investigations into the burden of these diseases (23) (24) (25) (26) . In addition to cardiac dysfunction and heart failure, the spectrum of cardiovascular effects related to cancer therapies (spanning many cancer therapeutics and radiation treatments) includes, but is not limited to, arrhythmias, valvular heart disease, accelerated atherosclerosis, and pericardial disease. The reader is invited to in-depth reviews of these broad investigational areas (27) (28) (29) (30) (31) (32) (33) .
The growth of research and clinical activities, evidenced by an exponential increase in the number of publications in the field (Figure 2) , has set the foundation for a new discipline, aimed not only at screening, preventing, and treating CV effects of cancer therapies, but also at forming a partnership in providing comprehensive CV care for patients with cancer and cancer survivors (1-3).
EXISTING CARDIO-ONCOLOGY PROGRAMS:
A VANGUARD?
Growing clinical demand has resulted in the emer- Search term "cardio oncology"
As of April 14, 2015 single cardiologist with expertise in the area, and 12% currently offer no cardio-oncology services but plan to add them within the next year. 
BARRIERS TO ESTABLISHMENT OR EXPANSION OF
CARDIO-ONCOLOGY SERVICES. Lack of national guidelines and lack of funding were the most frequently cited barriers to the establishment of a cardiooncology service (both cited by 44%), followed by Enhancement of efforts and funding in all areas including, but not limited to, outcomes and epidemiology, basic science, translational science, and clinical trials.
Critical integration and validation of data, mostly from single academic institutions, to confirm clinical effectiveness and inform clinical practice activities with eventual guideline generation.
Education MD Anderson and ICOS organize biannual conferences focused on CV effects of cancer therapies. MD Anderson web-based audiovisual lecture series on MD Anderson Practices in Onco-Cardiology discuss topics relevant to heart disease in patients with cancer and cardiotoxicity (40).
ICOS holds monthly webinars with live discussions of clinical cases and cardio-oncology topics (41).
Cancer and the Heart textbook by MD Anderson authors addresses broad aspects of cardiotoxicity (42) . ACC.15 featured "Cardio-Oncology Intensive," a dedicated half-day session with multidisciplinary participation. ASCO's CME modules focus on the oncologist's perspective and medical concerns related to CV toxicity (43,44).
Further development of educational content for cardiology providers covering rapidly evolving areas, such as targeted therapeutics, novel cancer-treatment combination therapy regimens, prevention, and role of cardiologists in survivorship programs. Further development of tools for knowledge dissemination, such as CME courses, online tools and applications, workshops, and integration with national and international conferences. Collaboration with oncology professional societies in development and dissemination of educational materials for oncology providers.
Training Only a few institutions offer advanced training in cardiooncology. There are no advanced training standards.
Development of cardio-oncology-specific competencies, training assessment tools, and curricular milestones based on COCATS recommendations (36) . This will include development of criteria and standardization of advanced training (Level II and III training). Successful examples of CV areas included in COCATS 4 include CV prevention, vascular medicine, critical care cardiology, and others (36) .
Collaborations of stakeholders NCI-NHLBI Workshop on cardiotoxicity highlighted the role of partnership between different government and regulatory agencies and professional societies (31) . ASCO and ACC have formed a working group charged to explore opportunities for collaboration. 
ROADMAP TO THE NEXT LEVEL
The survey results document a widespread appreciation of the importance of CV concerns in patients with cancer and a recognized need to improve the care of these patients through provision of specialized services. However, the survey also notes significant barriers. Plans to develop cardio-oncology must recognize both the opportunities and the potential hurdles. The ACC's recognition of the importance of this area and dedication to its advancement is manifest by the recent creation of a member section in cardio-oncology, which is a major step forward.
In planning for this section, the Cardio-Oncology Working Group considered current and future opportunities in broad areas of best clinical practices, research, education, and training ( Table 1) . The activities listed represent an arbitrary and narrow sample that is evolving rapidly (and will be outdated soon) 
